Our Month of May 2023

Dear Clients and Partners,

We are pleased to report notable developments and achievements from our contract manufacturing facility in Cape Town, South Africa, for May 2023.

A sense of momentum characterizes our current phase, defined by the predictability and consistency of our product delivery. Being 18 months into our license to manufacture medical cannabis products, we are on track for steady growth, fulfilling increasing demand and facilitating monthly product rotations, while simultaneously driving innovation. It is with anticipation and eagerness that we look to the future.

Staffing Updates

We have bolstered our team with two essential additions in May, thereby enhancing our commitment to excellence and innovation in Good Manufacturing Practices (GMP).

Kelisha Ramnarain has joined us as Quality Assurance Pharmacist. With her robust expertise from organizations like Nutrapharm Manufacturing Industries, she brings a wealth of knowledge in overseeing production processes, batch record auditing, and release, maintaining cGMP, and managing change control and deviations. Her appointment fortifies our ability to deliver on our promise of high-quality GMP medical cannabis products.

Lutendo Mathelemusa, our new Senior Quality Control Laboratory and Documentation Officer, strengthens our quality control operations and facilitates our expansion plans. With extensive experience in companies like Biovac, Spec Pharma, Pharma-Q, and Be-Tabs (Sun Pharma), she will enhance our in-house testing and stability testing capabilities while ensuring rigorous GMP reporting standards.

Global Market Trends

Germany continues to lead in products such as flowers, formulated extracts, and Dronabinol, while the Australian market is showing steady growth. Australia has been our key focus for the past nine months as its demand for medical cannabis escalates.

In May, we successfully completed our largest order to date for Australia. Our ability to deliver six proprietary chemo-type specific formulations for specific indications, while maintaining 100% chemo-type specifics of the original cultivar under GMP, is a testament to our team’s dedication. Our commitment to chemo-type specific medical cannabis formulations ensures predictability and consistency, allowing physicians to select chemo-types specific to patient needs, thus minimizing potential side effects.

As part of our pharmaceutical offerings, we continue to advance our knowledge and development of natural Dronabinol. We aim to soon release this natural, stable, and affordable Active Pharmaceutical Ingredient (API) for use in further research, development, formulation, and compounding, while also focusing on the registration of this molecule over time.

Looking Ahead

As we close the first half of 2023, we reflect on a period marked by enthusiasm, determination, and successful execution of our projects. June will be dedicated to research and development, innovation, and establishing new projects. We will continue to prioritize our European expansion, particularly focusing on the development of Dronabinol drops, and prepare for the market launch following our stability testing programs.

We thank you for your ongoing support and look forward to sharing more updates as we continue to innovate and expand.